Apr 6, 2017
Partly as a result of the O’Neill report, a consortium comprising UK biotech companies with cooperation from counterparts in the U.S. will make available up to $48 million in funding to expedite development of new antibiotics.
The group known as CARB-X (Combatting Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) would invest initially $24 million among 11 biotechnology companies. Depending on progress, an additional $24 million will be available. Three of the eleven projects will involve new classes of antibiotics.
Dr. Tim Jinks of the Wellcome Trust stated “Without effective drugs, doctors cannot treat patients.” He added “antibiotic resistance is a huge global health challenge and is getting worse.” The Executive Director of CARB-X, Keven Outterson of Boston University stated “By accelerating promising research it is our hope that we can speed up the delivery of new effective antibacterials, vaccines, devices in rapid diagnostics to patients who need them.